BioNTech SE (BNTX) Reports Q1 EPS of EUR14.24, Reiterates FY22 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
BioNTech Announces First Quarter Financial Results and Corporate Update
May 9, 2022 6:01 AM EDTFirst quarter revenues of 6.4Â billion1, net income of 3.7Â billion and fully diluted earnings per share of 14.24 ($15.972)Reiterates BioNTech COVID-19 2022 vaccine revenue guidance of 13 billion to 17 billionFirst-in-class CAR-T program targeting CLDN-6 (BNT211) in solid tumors showed manageable safety profile and signs of clinical activity; preliminary Phase 1/2 data presented at AACR Annual Meeting 2022Continued pipeline expansion to 16 clinical stage oncology programs in 20 ongoing clinical trialsÂ
Conference call and webcast scheduled for May 9, 2022, at 8:00 am ET (2:00 pm CET)
... More